局部rabibismane作为中度或重度糖尿病足部感染的辅助疗法:一个1b期随机,多中心,双盲,安慰剂控制的试验
Benjamin A Lipsky1, Paul J Kim2, Brian Murphy3
1Department of Medicine, University of Washington, Seattle, Washington, USA.
International wound journal
|April 3, 2024
概括
局部pravibismane在治疗慢性糖尿病足感染方面显示出安全性和潜在的有效性. 与安慰剂相比,这种抗感染药物减少了的大小和下肢截肢.
科学领域:
- 传染性疾病 传染性疾病
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病足 (DFU) 是糖尿病的一个严重并发症,经常导致严重的感染和截肢.
- 目前对受感染的DFU的治疗有局限性,需要新的治疗方法.
研究的目的:
- 评估Pravibismane的安全性和有效性,这是一种新的广泛的局部抗感染药物,用于管理中度至重度的慢性DFU感染.
- 为了评估局部rabibismane的全身吸收和耐受性.
主要方法:
- 第1b期,随机,双盲,安慰剂控制,多中心研究.
- 39名参与者接受了拉维斯曼;13名接受了安慰剂.
- 通过临床观察和全血样本的药理动力学分析来评估安全性.
主要成果:
- 普拉维比斯曼被很好地容忍,系统吸收最小 (血液度低于0.5 ng/mL).
- 与安慰剂相比,Pravibismane治疗导致的大小减少了3倍 (85%vs30%).
- 与相关的下肢截肢在pravibismane组中是6倍低的 (2.6%对15.4%).
结论:
- 局部pravbismane是安全的,并显示在治疗感染的慢性糖尿病足的潜在有效性.
- 普拉维比斯曼可以通过减少的大小和预防截肢来改善伤口愈合.
- 需要进一步的研究来证实这些有希望的发现.
相关概念视频
Blind Procedures
10.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.8K
Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K


